Recently, off-label use of anti-tumor necrosis factor agents for BD has increased, suggesting that TNF blockade represents an important therapeutic approach for patients with severe and resistant BD, but randomized controlled trials are lacking[7,21-23]. This evidence concerns the gene TNF and Behcet disease.